# Journal of Dermatological Treatment

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/journal-of-dermatological-treatment/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 0954-6634 |
| ISSNs | 0954-6634,1471-1753 |
| OpenAlex ID | https://openalex.org/S21432770 |
| Publisher | Informa |

## Journal papers

Showing 12 of 14.

- [A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis](https://scholariq.org/papers/a-systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of-the/)
- [Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis](https://scholariq.org/papers/real-life-experience-on-effectiveness-and-safety-of-dupilumab-in-adult-patients/)
- [Redefining the therapeutic objective in psoriatic patients candidates for biological therapy](https://scholariq.org/papers/redefining-the-therapeutic-objective-in-psoriatic-patients-candidates-for/)
- [Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)](https://scholariq.org/papers/sustained-response-with-ixekizumab-treatment-of-moderate-to-severe-psoriasis/)
- [Vehicles for atopic dermatitis therapies: more than just a placebo](https://scholariq.org/papers/vehicles-for-atopic-dermatitis-therapies-more-than-just-a-placebo/)
- [Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity](https://scholariq.org/papers/early-development-and-qualitative-evidence-of-content-validity-for-the-psoriasis/)
- [Patient and physician preferences for atopic dermatitis injection treatments in Japan](https://scholariq.org/papers/patient-and-physician-preferences-for-atopic-dermatitis-injection-treatments-in/)
- [Management of periocular basal cell carcinoma by Mohs micrographic surgery](https://scholariq.org/papers/management-of-periocular-basal-cell-carcinoma-by-mohs-micrographic-surgery/)
- [Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study](https://scholariq.org/papers/efficacy-and-safety-of-bilastine-in-reducing-pruritus-in-patients-with-chronic/)
- [Long-pulsed 1064-nm Nd:YAG laser significantly improves keratosis pilaris: a randomized, evaluator-blind study](https://scholariq.org/papers/long-pulsed-1064-nm-nd-yag-laser-significantly-improves-keratosis-pilaris-a/)
- [Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective](https://scholariq.org/papers/assessment-of-the-benefit-of-achieving-complete-versus-almost-complete-skin/)
- [Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries](https://scholariq.org/papers/cost-per-pasi-75-responder-of-calcipotriol-plus-betamethasone-dipropionate/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.